ATE224918T1 - Zusammensetzung zur hemmung der thromboseentstehung - Google Patents
Zusammensetzung zur hemmung der thromboseentstehungInfo
- Publication number
- ATE224918T1 ATE224918T1 AT96302311T AT96302311T ATE224918T1 AT E224918 T1 ATE224918 T1 AT E224918T1 AT 96302311 T AT96302311 T AT 96302311T AT 96302311 T AT96302311 T AT 96302311T AT E224918 T1 ATE224918 T1 AT E224918T1
- Authority
- AT
- Austria
- Prior art keywords
- thrombosis
- clot
- thrombin
- compositions
- thrombus
- Prior art date
Links
- 208000007536 Thrombosis Diseases 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000015572 biosynthetic process Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 108090000190 Thrombin Proteins 0.000 abstract 3
- 229960004072 thrombin Drugs 0.000 abstract 3
- 208000006011 Stroke Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 206010002388 Angina unstable Diseases 0.000 abstract 1
- 206010003178 Arterial thrombosis Diseases 0.000 abstract 1
- 206010051055 Deep vein thrombosis Diseases 0.000 abstract 1
- 102000009123 Fibrin Human genes 0.000 abstract 1
- 108010073385 Fibrin Proteins 0.000 abstract 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
- 102000004032 Heparin Cofactor II Human genes 0.000 abstract 1
- 108090000481 Heparin Cofactor II Proteins 0.000 abstract 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 abstract 1
- 208000010378 Pulmonary Embolism Diseases 0.000 abstract 1
- 208000007814 Unstable Angina Diseases 0.000 abstract 1
- 206010047249 Venous thrombosis Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 1
- 125000003172 aldehyde group Chemical group 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 238000000502 dialysis Methods 0.000 abstract 1
- 230000003292 diminished effect Effects 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 229950003499 fibrin Drugs 0.000 abstract 1
- 229960002897 heparin Drugs 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
- 230000000415 inactivating effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 abstract 1
- 239000003055 low molecular weight heparin Substances 0.000 abstract 1
- 229940127215 low-molecular weight heparin Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
- C08B37/0078—Degradation products
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41233295A | 1995-03-31 | 1995-03-31 | |
| US48587295A | 1995-06-07 | 1995-06-07 | |
| US08/540,324 US5744457A (en) | 1995-03-31 | 1995-10-06 | Compositions and methods for inhibiting thrombogenesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE224918T1 true ATE224918T1 (de) | 2002-10-15 |
Family
ID=27410936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96302311T ATE224918T1 (de) | 1995-03-31 | 1996-04-01 | Zusammensetzung zur hemmung der thromboseentstehung |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0735050B1 (de) |
| AT (1) | ATE224918T1 (de) |
| DE (1) | DE69623840D1 (de) |
| GB (1) | GB2299998B (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5767269A (en) * | 1996-10-01 | 1998-06-16 | Hamilton Civic Hospitals Research Development Inc. | Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics |
| AU7753898A (en) * | 1997-06-06 | 1998-12-21 | Hamilton Civic Hospitals Research Development, Inc. | Modified low molecular weight heparin that inhibits clot associated coagulation factors |
| EP1161279A1 (de) * | 1999-03-11 | 2001-12-12 | Du Pont Pharmaceuticals Company | Behandlung von thrombose mit kombinationen aus factor xa hemmern mit aspirin, gewebe-plasminogenaktivatoren (tpa), gpiib/iiia antagonisten, niedermolekulare heparin oder heparin |
| US6794412B1 (en) | 1999-03-11 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin |
| US6346517B1 (en) | 1999-03-11 | 2002-02-12 | Bristol-Myers Squibb Pharma Company | Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders |
| US7575886B2 (en) | 2002-03-11 | 2009-08-18 | Momenta Pharmaceuticals, Inc. | Analysis of sulfated polysaccharides |
| US9139876B1 (en) | 2007-05-03 | 2015-09-22 | Momenta Pharmacueticals, Inc. | Method of analyzing a preparation of a low molecular weight heparin |
| US8592393B2 (en) * | 2007-11-02 | 2013-11-26 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| EP2207811B1 (de) * | 2007-11-02 | 2017-01-04 | Momenta Pharmaceuticals, Inc. | Nicht gerinnungshemmende polysaccharidzusammensetzungen |
| US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| WO2009059284A2 (en) * | 2007-11-02 | 2009-05-07 | Momenta Pharmaceuticals, Inc. | Non-anticoagulant polysaccharide compositions |
| CN102985443B (zh) | 2010-04-16 | 2017-05-10 | 动量制药公司 | 组织靶向 |
| US10017585B2 (en) | 2010-06-17 | 2018-07-10 | Momenta Pharmaceuticals, Inc. | Methods and compositions for promoting hair growth |
| WO2012115952A1 (en) | 2011-02-21 | 2012-08-30 | Momenta Pharmaceuticals, Inc. | Evaluating heparin preparations |
| HRP20180124T1 (hr) * | 2011-12-19 | 2018-02-23 | Dilafor Ab | Glikozaminoglikani koji nisu antikoagulanti koji sadrže ponavljajuću jedinicu disaharida i njihova medicinska upotreba |
| WO2013095215A1 (en) * | 2011-12-19 | 2013-06-27 | Dilaforette Ab | Low anticoagulant heparins |
| EP3003324A4 (de) | 2013-05-28 | 2017-01-25 | Momenta Pharmaceuticals, Inc. | Pharmazeutische zusammensetzungen |
| WO2014193816A1 (en) * | 2013-05-28 | 2014-12-04 | Momenta Phamaceuticals, Inc. | Polysaccharide compositions and related methods |
| GB2515315A (en) * | 2013-06-19 | 2014-12-24 | Dilafor Ab | New Processes |
| GB202217216D0 (en) * | 2022-11-17 | 2023-01-04 | Bhogal Pervinder Singh | Preparation of medium molecular weight heparin |
| WO2025106117A1 (en) * | 2023-11-17 | 2025-05-22 | Glycos Biomedical Ltd. | Medium molecular weight heparin |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1136620A (en) * | 1979-01-08 | 1982-11-30 | Ulf P.F. Lindahl | Heparin fragments having selective anticoagulation activity |
| US4916219A (en) * | 1985-03-28 | 1990-04-10 | University Of Iowa Research Foundation | Oligosaccharide heparin fragments as inhibitors of complement cascade |
| FR2614026B1 (fr) * | 1987-04-16 | 1992-04-17 | Sanofi Sa | Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques |
| ES2053953T3 (es) * | 1988-08-24 | 1994-08-01 | Akzo Nv | Uso de fracciones de heparina o fragmentos de heparina. |
| SE9002550D0 (sv) * | 1990-08-01 | 1990-08-01 | Kabivitrum Ab | Heparinfragment |
| FR2687158B1 (fr) * | 1992-02-07 | 1995-06-30 | Rhone Poulenc Rorer Sa | Polysaccharides sulfates, procede de preparation, composition pharmaceutique et utilisation. |
-
1996
- 1996-04-01 GB GB9606881A patent/GB2299998B/en not_active Expired - Fee Related
- 1996-04-01 EP EP96302311A patent/EP0735050B1/de not_active Expired - Lifetime
- 1996-04-01 AT AT96302311T patent/ATE224918T1/de not_active IP Right Cessation
- 1996-04-01 DE DE69623840T patent/DE69623840D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0735050A2 (de) | 1996-10-02 |
| EP0735050A3 (de) | 1997-01-22 |
| GB9606881D0 (en) | 1996-06-05 |
| EP0735050B1 (de) | 2002-09-25 |
| GB2299998A (en) | 1996-10-23 |
| DE69623840D1 (de) | 2002-10-31 |
| GB2299998B (en) | 1997-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE224918T1 (de) | Zusammensetzung zur hemmung der thromboseentstehung | |
| WO1996029973A3 (en) | Compositions and methods for inhibiting thrombogenesis | |
| Lijnen et al. | Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. | |
| CA1136620A (en) | Heparin fragments having selective anticoagulation activity | |
| Klement et al. | Blood-compatible biomaterials by surface coating with a novel antithrombin–heparin covalent complex | |
| AU596951B2 (en) | Blood coagulation inhibiting proteins, processes for preparing them and their uses | |
| CA2084301C (en) | Heparin derivatives and process for the preparation thereof | |
| HK1045532A1 (zh) | 抑制与凝结有关凝结因子的肝素成份 | |
| US8003623B2 (en) | Mixtures of sulfated oligosaccharides | |
| Valentin et al. | Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans | |
| Dryjski et al. | Effect of glycosaminoglycans and antithrombin III on uptake and inhibition of thrombin by the vascular wall | |
| Budzynski et al. | The interference of plasmic degradation products of human crosslinked fibrin with clot formation | |
| Patel et al. | Covalent antithrombin–heparin complexes | |
| Swedenborg et al. | Inactivation of thrombin by the aortic endothelium | |
| Spellman et al. | Comparison of polymerization of ancrod and thrombin fibrin monomers | |
| DE60039437D1 (de) | Verwendung der sulfatierten polysacchariden zur behandlung von thrombosen | |
| Dryjski et al. | Thrombin activity appearing on the vessel wall after trauma | |
| Godal | The influence of heparin on the fibrin clot | |
| Nader et al. | Structural requirements of heparin disaccharides responsible for hemorrhage: reversion of the antihemostatic effect by ATP | |
| Cofrancesco et al. | GAGs-Potentiated Inhibition of Thrombin, Factor Xa and Plasmin in Plasma and in a Purified System Containing Antithrombin III–Correlation with Total Charge Density | |
| Ferrari et al. | Treatment of the heparin-induced thrombosis-thrombocytopenia syndrome by very low dose streptokinase | |
| Tarvady et al. | Effect of heparin on wound healing | |
| Edgar et al. | The effect of temperature on formation of fibrin complexes | |
| Viigimaa et al. | Platelet aggregation, sensitivity to prostaglandin E1 and thromboxane A2 release in recombinant hirudin-and heparin-anticoagulated blood | |
| Breddin | Heparinoids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |